title: Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
abstract: Combination vaccines of the NY-ESO-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible.
authors.affiliation: Department of Haematology and Oncology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie 514-8507, Japan. aoki@kaiseihp.com
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Aoki
authors.forename: Shugo
authors.initials: S
authors.lastname: Ueda
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Shigehisa
authors.initials: S
authors.lastname: Kitano
authors.forename: Michiko
authors.initials: M
authors.lastname: Hirayama
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ikeda
authors.forename: Hideki
authors.initials: H
authors.lastname: Toyoda
authors.forename: Kyosuke
authors.initials: K
authors.lastname: Tanaka
authors.forename: Michiyuki
authors.initials: M
authors.lastname: Kanai
authors.forename: Arimichi
authors.initials: A
authors.lastname: Takabayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imai
authors.forename: Taizo
authors.initials: T
authors.lastname: Shiraishi
authors.forename: Eiichi
authors.initials: E
authors.lastname: Sato
authors.forename: Hisashi
authors.initials: H
authors.lastname: Wada
authors.forename: Eiichi
authors.initials: E
authors.lastname: Nakayama
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Takei
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Katayama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiku
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kageyama
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood; D000917:Antibody Formation; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D004938:Esophageal Neoplasms / Q000628:therapy; D005260:Female; D005936:Glucans / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008565:Membrane Proteins / Q000276:immunology*; D008875:Middle Aged; D010844:Picibanil / Q000276:immunology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D017778:Vaccines, Combined / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D005936:Glucans; D007074:Immunoglobulin G; D008565:Membrane Proteins; D010844:Picibanil; D018719:Erb-b2 Receptor Tyrosine Kinases; D011994:Recombinant Proteins; D017778:Vaccines, Combined; C528170:CHP-HER2 vaccine; C104948:CTAG1B protein, human; C009109:pullulan